title: ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference?
authors.affiliation: Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Wiebe
authors.forename: W
authors.initials: W
authors.lastname: Harringer
authors.forename: T
authors.initials: T
authors.lastname: Wahlers
authors.forename: U
authors.initials: U
authors.lastname: Franke
authors.forename: M
authors.initials: M
authors.lastname: Strüber
authors.forename: M
authors.initials: M
authors.lastname: Hamm
authors.forename: J
authors.initials: J
authors.lastname: Cremer
authors.forename: A
authors.initials: A
authors.lastname: Haverich
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000453:epidemiology* / Q000473:pathology / Q000517:prevention & control; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D016041:Heart-Lung Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016040:Lung Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011183:Postoperative Complications; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents